Alexander M M Eggermont Selected Research

COVID-19

1/2022	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
1/2022	Therapeutic vaccines for breast cancer: Has the time finally come?
1/2021	SARS-CoV-2 vaccines for cancer patients: a call to action.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alexander M M Eggermont Research Topics

Disease

141	Melanoma (Melanoma, Malignant) 03/2024 - 03/2002
119	Neoplasms (Cancer) 02/2024 - 01/2002
45	Neoplasm Metastasis (Metastasis) 03/2024 - 01/2003
26	Sarcoma (Soft Tissue Sarcoma) 01/2021 - 01/2002
11	Hyperthermia 01/2021 - 04/2010
9	Necrosis 02/2015 - 05/2003
7	Lymphatic Metastasis 11/2020 - 10/2005
6	Breast Neoplasms (Breast Cancer) 01/2022 - 05/2003
6	Rectal Neoplasms (Rectal Cancer) 03/2013 - 05/2005
5	Renal Cell Carcinoma (Grawitz Tumor) 10/2016 - 02/2003
4	Margins of Excision 11/2023 - 08/2002
3	Disease Progression 10/2023 - 06/2011
3	COVID-19 01/2022 - 01/2021
3	Fatigue 01/2015 - 10/2009
3	Osteosarcoma (Osteogenic Sarcoma) 07/2005 - 01/2002
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 11/2023 - 06/2011
2	Exanthema (Rash) 11/2022 - 06/2011
2	Diarrhea 06/2011 - 01/2002
2	Hemorrhage 09/2006 - 05/2003
2	Edema (Dropsy) 07/2005 - 05/2005
1	Pain (Aches) 02/2024
1	Hematologic Neoplasms (Hematological Malignancy) 01/2023
1	Glioblastoma (Glioblastoma Multiforme) 01/2023
1	Pathologic Complete Response 01/2023
1	Brain Neoplasms (Brain Tumor) 01/2023

Drug/Important Bio-Agent (IBA)

34	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2014 - 01/2002
24	Melphalan (Alkeran)FDA LinkGeneric 02/2015 - 01/2003
20	pembrolizumabIBA 03/2024 - 11/2017
20	Liposomes (Liposome)IBA 01/2018 - 01/2002
18	InterferonsIBA 01/2018 - 10/2002
14	IpilimumabIBA 01/2022 - 10/2010
14	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2018 - 01/2002
11	Interferon-alpha (Interferon Alfa)IBA 07/2013 - 10/2002
10	Immune Checkpoint InhibitorsIBA 02/2024 - 06/2015
10	Biomarkers (Surrogate Marker)IBA 01/2023 - 07/2013
10	CytokinesIBA 07/2013 - 10/2002
9	Proteins (Proteins, Gene)FDA Link 01/2019 - 01/2002
6	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2023 - 01/2012
6	Dacarbazine (DIC)FDA LinkGeneric 03/2014 - 08/2004
5	dabrafenibIBA 01/2023 - 01/2015
5	NivolumabIBA 01/2023 - 06/2015
5	VaccinesIBA 01/2022 - 02/2005
5	AntibodiesIBA 01/2018 - 06/2009
5	Monoclonal AntibodiesIBA 01/2016 - 10/2010
5	Interleukin-2 (IL2)IBA 04/2011 - 05/2005
4	trametinibIBA 01/2023 - 11/2017
4	AntigensIBA 01/2018 - 07/2013
4	LipidsIBA 03/2016 - 08/2010
4	liposomal doxorubicin (Doxil)FDA Link 03/2016 - 01/2002
4	SphingolipidsIBA 08/2015 - 01/2011
4	Messenger RNA (mRNA)IBA 07/2013 - 05/2005
4	Monophenol Monooxygenase (Tyrosinase)IBA 12/2010 - 07/2003
4	Histamine (Histamine Dihydrochloride)FDA Link 04/2007 - 11/2004
3	Dihydrotachysterol (AT 10)IBA 11/2022 - 03/2016
3	ParaffinIBA 01/2013 - 12/2010
3	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 12/2010 - 12/2008
3	Interferon alpha-2 (Roferon-A)FDA Link 05/2010 - 10/2005
3	Cisplatin (Platino)FDA LinkGeneric 07/2009 - 03/2005
3	salicylhydroxamic acid (SHAM)IBA 02/2007 - 05/2005
3	member 1 small inducible cytokine subfamily EIBA 12/2006 - 09/2006
2	COVID-19 VaccinesIBA 01/2021 - 01/2021
2	B7-H1 AntigenIBA 11/2020 - 10/2016
2	Interferon-alpha2bIBA 01/2020 - 07/2004
2	LigandsIBA 05/2018 - 09/2011
2	saponin QA-21V1 (QS21)IBA 01/2018 - 10/2013
2	G(M2) Ganglioside (Ganglioside GM2)IBA 01/2018 - 10/2013
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 11/2017 - 07/2009
2	ChromatinIBA 10/2016 - 04/2014
2	Tissue Inhibitor of Metalloproteinase-3IBA 10/2016 - 01/2014
2	Conditioned Culture MediaIBA 01/2016 - 01/2014
2	Mitoxantrone (Novantrone)FDA LinkGeneric 08/2015 - 04/2015
2	VemurafenibIBA 01/2015 - 06/2011
2	fotemustine (Muphoran)IBA 03/2014 - 10/2005
2	Immunologic Adjuvants (Immunologic Adjuvant)IBA 07/2013 - 11/2005
2	Cadherins (E-Cadherin)IBA 11/2012 - 05/2010
2	MART-1 AntigenIBA 12/2010 - 12/2009
2	AutoantibodiesIBA 05/2010 - 06/2009
2	Monoamine Oxidase (MAO)IBA 10/2009 - 01/2005
2	Peptides (Polypeptides)IBA 11/2005 - 07/2003
2	Amino Acids FDA Link 07/2004 - 07/2003
2	Neutral Amino AcidsIBA 07/2004 - 07/2003
2	BiopterinsIBA 07/2004 - 07/2003
2	NeopterinIBA 07/2004 - 07/2003
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 02/2024
1	Acetaminophen (Paracetamol)FDA LinkGeneric 02/2024
1	Antineoplastic Agents (Antineoplastics)IBA 10/2023
1	Metformin (Glucophage)FDA LinkGeneric 01/2023
1	Lipase (Acid Lipase)FDA Link 11/2022

Therapy/Procedure

88	Therapeutics 03/2024 - 01/2002
29	Immunotherapy 02/2024 - 08/2002
25	Drug Therapy (Chemotherapy) 01/2021 - 01/2002
14	Lymph Node Excision (Lymph Node Dissection) 01/2022 - 08/2002
9	Surgical Amputation (Amputations) 10/2011 - 01/2003
8	Radiotherapy 11/2023 - 05/2005
5	Neoadjuvant Therapy 01/2018 - 10/2011
3	Adjuvant Radiotherapy 11/2023 - 02/2011
3	Limb Salvage 02/2006 - 01/2003
2	Induced Hyperthermia (Thermotherapy) 01/2016 - 04/2013
2	Immunomodulation 03/2014 - 09/2011
2	Injections 10/2007 - 07/2005